Next week, 6,000 HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
Very early initiation of ART, followed by several years of viral suppression, can have a relatively common outcome of testing HIV negative using rapid HIV tests.
Many trans women living with HIV may contract the virus because they or their sexual partners are intravenous drug users (IDU), finds a new study.
It turns out that you can trust gay men at high risk for HIV to take care of their health -- even if they have to remember to take an HIV prevention pill before sex.
Janssen Vaccines and Prevention B.V. is now rapidly advancing an experimental prime-boost HIV vaccine regimen, with plans announced to launch a large-scale "proof of concept" efficacy trial in women in late 2017/early 2018.
Dolutegravir (DTG) was superior to lopinavir/ritonavir (LPV/r) in a comparison of DTG-based regimen versus the WHO-recommended second-line regimen.
Brief IAS 2017 summaries of ongoing research on pre-exposure prophylaxis (PrEP), evaluating its long-term effectiveness and safety, patient experiences, and alternative dosing schedules, such as an on-demand regimen.
Two interesting early studies on the investigational NRTI MK-8591 (EFdA) were presented at IAS 2017\. This compound is notable for a very high potency, a long-half life and the potential for use both as HIV treatment and for HIV prevention.
The findings could inform the debate on the merits of TDF, which is available in many regions as a less-costly generic, versus the more recently approved prodrug tenofovir alafenamide (TAF).
A review of HIV drugs in development that summarizes the most exciting new research over the previous year.